Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies

Related

• 

  Episode 143: Journal Club, Pediatric Retinal Detachment Surgery, Open Label Extension RISE and RIDE, BP Changes during Injections

  Jayanth Sridhar, MD

  Member Podcasts

  2018

• 

  Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy

  Judy E. Kim, MD, FASRS

  Chirag D. Jhaveri, MD, FASRS

  Michael S. Ip, MD

  Arshad M. Khanani, MD, MA, FASRS

  Jordana G Fein, MD, MS

  Dennis M. Marcus, MD

  Diana V Do, MD, FASRS

  Annual Meeting Talks

  2024

• 

  Characteristics and the Need for Supplementation Following 0.19mg Fluocinolone Acetonide (FAc) in Diabetic Macular Edema (DME) Patients

  Victor Hugo Gonzalez, MD

  Annual Meeting Talks

  2021